Proteome analysis of hepatocellular carcinoma by laser capture microdissection

Ai, Jian-Hua; Tan, Ye-Xiong; Ying, Wantao; Hong, Yi; Liu, Shuqing; Wu, Mengchao; Qian, Xiaohong; Wang, Hongyang

doi:10.1002/pmic.200500257

Cited by 65 publications

(44 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we also found that the WBC was higher in the PC + DM group than that in the common type 2 DM group (p = 0.002), indicating the presence of inflammation, which may be responsible for the lower APO-A1 concentration in PC + DM. The reduction of APO-A1 was also shown in other types of cancer such as ovarian and liver cancer [39,40]. These results are in accordance with our finding that APO-A1 is an independent risk factor for differentiating PC + DM from common type 2 diabetes.…”

Section: Discussionsupporting

confidence: 82%

Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer

Dong

Lou

et al. 2018

Digestion

View full text Add to dashboard Cite

Background: The purpose of this study was to find the factors that may be helpful for differentiating pancreatic cancer-associated diabetes mellitus (PC + DM) from common type 2 diabetes for the early diagnosis of pancreatic cancer. Methods: From January 2008 to August 2013, 171 patients with pancreatic cancer and new-onset diabetes were recruited for the study; 242 age- and gender-matched patients with common type 2 diabetes were also identified as control during the same period. The patient’s characteristics and laboratory parameters were compared between the 2 groups. Results: By multivariate logistic regression analysis, we found that body mass index (BMI), the age of onset of diabetes, hepatitis B virus (HBV) infection, total bilirubin (TBIL), alanine aminotransferase (ALT), creatinine (Cr), apolipoprotein-A1 (APO-A1), and white blood cell (WBC) were independent predictive factors for differentiating PC + DM from common type 2 diabetes; the areas under receiver operating characteristic curves were up to 0.815 for the combination of these 8 markers. Conclusions: These results suggest that BMI, the age of onset of diabetes, HBV infection, TBIL, ALT, Cr, APO-A1, and WBC are factors that could differentiate PC + DM from common type 2 diabetes and may be used for early diagnosis of pancreatic cancer.

show abstract

Section: Discussionsupporting

confidence: 82%

Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer

Dong

Lou

et al. 2018

Digestion

View full text Add to dashboard Cite

show abstract

“…In particular, MS is a powerful tool for resolving the complexity of cancer signaling pathways. With regard to HCC, qualitative proteomics has been performed on resected tumor material (12), laser-capture microdissected material from tissue sections (13,14), and primary hepatocytes or serum derived from patients (15,16). These studies (17,18) identified HCC biomarkers such as glutamine synthetase and heat shock protein 70 (Hsp70) that are currently in use for diagnosis (19,20).…”

mentioning

confidence: 99%

Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

Dazert

Colombi

Boldanova

et al. 2016

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Compensatory signaling pathways in tumors confer resistance to targeted therapy, but the pathways and their mechanisms of activation remain largely unknown. We describe a procedure for quantitative proteomics and phosphoproteomics on snap-frozen biopsies of hepatocellular carcinoma (HCC) and matched nontumor liver tissue. We applied this procedure to monitor signaling pathways in serial biopsies taken from an HCC patient before and during treatment with the multikinase inhibitor sorafenib. At diagnosis, the patient had an advanced HCC. At the time of the second biopsy, abdominal imaging revealed progressive disease despite sorafenib treatment. Sorafenib was confirmed to inhibit MAPK signaling in the tumor, as measured by reduced ribosomal protein S6 kinase phosphorylation. Hierarchical clustering and enrichment analysis revealed pathways broadly implicated in tumor progression and resistance, such as epithelial-to-mesenchymal transition and cell adhesion pathways. Thus, we describe a protocol for quantitative analysis of oncogenic pathways in HCC biopsies and obtained first insights into the effect of sorafenib in vivo. This protocol will allow elucidation of mechanisms of resistance and enable precision medicine.

show abstract

“…Previous studies have reported the diagnostic value of ApoA-1 and proApolipoprotein A1 (the precursor of ApoA-1) in tumor diagnosis. Decreased levels of ApoA-1 were found in a variety of cancers [18][19][20][21][22][23], but pro-ApoA-1 increased in breast cancer [24]. Marchi et al found that pro-ApoA-1 significantly increased (p<0.05) in lung cancer patients with brain metastases [25].…”

Section: Discussionmentioning

confidence: 99%

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Huang¹,

Ding²,

Li³

et al. 2012

neo

View full text Add to dashboard Cite

Purpose: To find potential serum biomakers that can predict clinical outcome upon treatment in non-small cell lung cancer (NSCLC) by analyzing differential proteins in serum with different sensitivity of chemoradiotherapy (CRT).Materials and Methods: Sera were collected from 37 NSCLC patients before they were treated with concurrent cisplatinbased CRT. According to the outcome of CRT, the patients were divided into sensitive group and resistant one. The proteins in sera were separated by two-dimensional gel electrophoresis after the high abundance proteins were removed from sera. The significantly differentially expressed proteins between two groups were analyzed by liquid chromatography and tendem mass spectrometry (LC-MS/MS). Then, an additional 50 serum samples were used for ELISA analysis to validate the identified proteins that we got in the experiment.Results: Proteins in sera of each group were successfully separated on 2D gels. There were significant discrepancies in serum protein expression between NSCLC patients with different CRT sensitivity. Among eight differently expressed proteins, six proteins were successfully identified with five of which higher expressed and one lower expressed in resistant group. The increased Alpha-1-antitrypsin (α1-AT) level in resistant group comparing to sensitive one were validated by ELISA analysis (p<0.05).Conclusions: Proteomic approach may serve as a useful method in detecting the potential biomarkers for predicting the outcome of treatment in NSCLC patients. NSCLC patients with high α1-AT level in serum before CRT may have a worse treatment outcome.

show abstract

Proteome analysis of hepatocellular carcinoma by laser capture microdissection

Cited by 65 publications

References 35 publications

Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer

Predictive Factors for Differentiating Pancreatic Cancer-Associated Diabetes Mellitus from Common Type 2 Diabetes Mellitus for the Early Detection of Pancreatic Cancer

Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy

Contact Info

Product

Resources

About